Velpatasvir (formerly known as GS5816; GS-5816; VEL; trade name Vosevi) is a potent, selective, second-generation Hepatitis C virus NS5A protease inhibitor approved for clinical use with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes. It inhibits hepatitis C viral replication through acting on the crucial ‘membranous web’ that facilitates RNA […]

Deferiprone (tradename Ferriprox) is novel, potent and orally bioactive iron-chelating drug used for transfusional iron overload clinically.

Grazoprevir sodium salt (MK5172; MK-5172), the sodium salt form of grazoprevir, is an inhibitor of the Hepatitis C Virus NS3/4A Protease (IC50 = 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively) used in combination with the NS5A replication complex inhibitor elbasvir for HCV treatment. Grazoprevir was approved by FDA in 2016 […]

NM-107 (2′-C-Methylcytidine; 2’CMeC; 2′-C-MeC; mCyd; 2CMC) is a novel, potent and selective anti-viral agent acting as an inhibitor of the hepatitis C virus (HCV) NS5B polymerase.

RO-9187 is a novel and potent inhibitor of HCV virus replication with IC50 of 171 nM. RO-0622 and RO-9187 were excellent substrates for deoxycytidine kinase and were phosphorylated with efficiencies up to 3-fold higher than deoxycytidine. As compared with previous reports on ribonucleosides, higher levels of triphosphate were formed from RO-9187 in primary human hepatocytes, […]

PSI-7409 is a novel and active 5′-triphosphate metabolite of Sofosbuvir (PSI-7977). Sofosbuvir (also known as PSI-7977, GS-7977; trade names Sovaldi and Virunon) is a HCV NS5B polymerase inhibitor that is used for the treatment of chronic hepatitis C virus (HCV) infection. Sofosbuvir acts by inhibiting the RNA polymerase that the hepatitis C virus uses to […]